Table 3.
Univariable linear regression analyses of serum MPO levels (ng/mL)
| Unadjusted mean (95% CI) or N | Unadjusted relative change in MPO between groups or for every 1 unit increase in variable (95% CI) | p-value | |
|---|---|---|---|
| Psoriasis patients (N=100) | |||
| Psoriasis measures | |||
| Psoriasis | Control: N=53 | 2.48 (1.81, 3.38) | <0.001 |
| 1,140.9 ng/ml (886.9, 1,467.7) | |||
| Psoriasis: N=100 | |||
| 2,827.6 ng/ml (2,353.8, 3,396.7) | |||
| PASI | 1.00 (0.99, 1.02) | 0.924 | |
| BSA | 1.00 (0.99, 1.01) | 0.831 | |
| PGA | 1.08 (0.89, 1.30) | 0.445 | |
| Psoriasis duration | 0.99 (0.98, 1.00) | 0.395 | |
| # of systemic, light or biologic therapy over lifetime | 1.05 (0.96, 1.15) | 0.248 | |
| Among Concurrent PsA | No: N=86 | 1.17 (0.70, 1.99) | 0.553 |
| 2,765.1 ng/ml (2,270.3, 3,367.8) | |||
| Yes: N=14 | |||
| 3,243.6 ng/ml (1,989.7, 5,287.7) | |||
BSA: body surface area; CI: confidence interval; MPO: myeloperoxidase; N: count; PASI: psoriasis area and severity index; PGA: physicians’ global assessment; PsA: psoriatic arthritis.